Cited by 381Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsBone health and treatments

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Open access

Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.·2014·Blood

DOI 10.1182/blood-2013-11-538835PMC PMC3962162

Open this paper in CoChat — free account

Abstract

Key Points: Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2013-11-538835

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Self-citation
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Self-citation
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citation
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citation
Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 792
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation

Show all 43 references

Research works printed but not linked: 1

Rychack, 2011, Overcoming resistance; the use of pomalidomide (POM) and dexamethasone (DEX) in re-sensitizing lenalidomide (LEN)-resistant multiple myeloma (MM) cells., Haematologica, 96, S126

Sorted by citations

Items 101–200 of 381

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Venous thromboembolism in hematopoietic stem cell transplant recipients
Chaturvedi, S., Neff, A. T., Nagler, A., Savani, U. B., Mohty, M., & Savani, B. N. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.308 · Cited by 40
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Orlowski, R. Z., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0861 · Cited by 39
Self-citation
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
Driessen, C., Müller, R., Novak, U., Cantoni, N., Betticher, D. C., Mach, N., Rüfer, A., Mey, U., Samaras, P., Ribi, K., et al. (2018) · Blood · doi:10.1182/blood-2018-05-851170 · Cited by 39
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Richardson, P. G. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S. D., Lonial, S., Laubach, J. P., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.173 · Cited by 37
Self-citation
Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Maiese, E. M., Ainsworth, C., Moine, J.-G. L., Ahdesmäki, O., Bell, J. A., & Hawe, E. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.014 · Cited by 35
Novel p97/ VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells
Nishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 39
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Scheid, C., Reece, D. E., Beksaç, M., Spencer, A. G., Callander, N. S., Sonneveld, P., Kalimi, G. H., Cai, C., Shi, M. M., Scott, J. W., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12491 · Cited by 36
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
Siegel, D. S. D., Weisel, K. C., Dimopoulos, M. A., Baz, R., Richardson, P. G. G., Delforge, M., Song, K., Miguel, J. F. S., Moreau, P., Goldschmidt, H., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1177181 · Cited by 32
Self-citation
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 35
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
Richardson, P. G. G., Laubach, J. P., Munshi, N. C., & Anderson, K. C. (2014) · Hematology · doi:10.1182/asheducation-2014.1.255 · Cited by 33
Self-citation
Treating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 35
Self-citation
Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma
Abbi, K. K. S., Zheng, J., Devlin, S. M., Giralt, S., & Landau, H. J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.677 · Cited by 31
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers
Benková, K., Mihályová, J., Hájek, R., & Jelı́nek, T. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100758 · Cited by 32
Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience
Maciocia, N., Melville, A., Cheesman, S., Sharpley, F. A., Ramasamy, K., Streetly, M. J., Jenner, M. W., Benjamin, R., Schey, S., Maciocia, P. M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14547 · Cited by 30
Pomalidomide for multiple myeloma
Fouquet, G., Bories, C., Guidez, S., Renaud, L., Herbaux, C., Javed, S., Facon, T. T. F., & Leleu, X. P. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.966074 · Cited by 30
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 31
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
Cliff, E. R. S., Reynolds, G. K., Popat, R., Teh, B. W., Kesselheim, A. S., & Mohyuddin, G. R. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02197 · Cited by 30
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 30
Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 32
A review of the venous thrombotic issues associated with multiple myeloma
Fotiou, D., Gerotziafas, G., Kastritis, E., Dimopoulos, M. A., & Terpos, E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1194750 · Cited by 29
Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management
Patel, V. G., & Cornell, R. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0784-4 · Cited by 28
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Puig, N., Hernández, M. T., Rosiñol, L., González, E., de Arriba, F., Oriol, A., González‐Calle, V., Escalante, F., de la Rubia, J., Gironella, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00490-8 · Cited by 28
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium
LeBlanc, R., Bergstrom, D. J., Côté, J. A., Kotb, R. R., Louzada, M., & Sutherland, H. J. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.028 · Cited by 29
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16030415 · Cited by 36
New Approaches to Management of Multiple Myeloma
Genadieva-Stavric, S., Cavallo, F., & Palumbo, A. P. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0276-6 · Cited by 27
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Self-citation
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial
Bahlis, N. J., Siegel, D. S. D., Schiller, G. J., Samaras, C. J., Sébag, M., Berdeja, J. G., Ganguly, S., Matous, J., Song, K., Seet, C. S., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2030477 · Cited by 26
Self-citation
Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK/Akt/mTOR pathway and EGFR/FAAD proteins
jo, R. D. A. ⁄., Pessoa, J. B., Cruz, L. J., Chan, A. B., Miguel, E. D. C., Cavalcante, R. ⁄. M., Brito, G. A. D. C., Silva, H. F., Gasparotto, L. H. S., Guedes, P. M. D. M., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4179 · Cited by 26
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
Lee, D. H., & Fradley, M. G. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0618-y · Cited by 27
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
Salomon‐Perzyński, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Dytfeld, D., Zielińska, P., Wojciechowska, M., Hołojda, J., Robak, P. J., Pasternak, A., Knopińska‐Posłuszny, W., et al. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.05.001 · Cited by 25
The role of carfilzomib in relapsed/refractory multiple myeloma
Yee, A. J. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211019612 · Cited by 27
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
Hoy, S. M. (2017) · Drugs · doi:10.1007/s40265-017-0833-y · Cited by 25
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
Richardson, P. G. G., Harvey, R. D., Laubach, J. P., Moreau, P., Lonial, S., & Miguel, J. F. S. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1096773 · Cited by 24
Self-citation
A historical perspective on milestones in multiple myeloma research
Ribatti, D. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13003 · Cited by 29
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Luo, X., Du, X., Li, J.-L., Liu, X., & Meng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166640 · Cited by 23
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis
Moreau, P., Dimopoulos, M. A., Richardson, P. G. G., Siegel, D. S. D., Cavo, M., Corradini, P., Weisel, K. C., Delforge, M., O’Gorman, P., Song, K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12903 · Cited by 24
Self-citation
Managing renal complications in multiple myeloma
Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1210003 · Cited by 24
Plasma Cell Tumors
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Self-citation
Therapeutic progress in relapsed/refractory multiple myeloma
Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 26
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma
Oekelen, O. V., Amatangelo, M. D., Guo, M., Upadhyaya, B., Cribbs, A. P., Kelly, G., Patel, M., Kim‐Schulze, S., Flynt, E., Laganà, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101584 · Cited by 25
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Zamagni, E., Tacchetti, P., Pantani, L., & Cavo, M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456331 · Cited by 22
Pomalidomide for the treatment of relapsed–refractory multiple myeloma: a review of biological and clinical data
Offidani, M., Corvatta, L., Caraffa, P., Leoni, P., Pautasso, C., Larocca, A., & Palumbo, A. P. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.906904 · Cited by 23
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 22
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
Kastritis, E., Ρούσσου, Μ., Gavriatopoulou, M., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., Ziogas, D. C., Fotiou, D., Ntanasis‐Stathopoulos, I., Dialoupi, I., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000539 · Cited by 22
Identification and characterization of related substances in pomalidomide by hyphenated LC–MS techniques
Lu, P., Wang, L., Song, M. O., & Hang, T. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.05.018 · Cited by 22
Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation
JOSEPH, D. R., El-Jawahri, A. R., LeBlanc, T. W., & Roeland, E. J. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.01.012 · Cited by 21
Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses
Phan, V. T. X., Ito, T., Inaba, M., Azuma, Y., Kibata, K., Inagaki‐Katashiba, N., Tanaka, A., Satake, A., & Nomura, S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001410 · Cited by 21
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Gasparetto, C., Bowles, K. M., Abdallah, A.-O. A., Morris, L. J., Mander, G., Coppola, S., Wang, J., Ross, J. A., Bueno, O. F., Arriola, E. L., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.029 · Cited by 20
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
Hartley-Brown, M. A., Mo, C. C., Nadeem, O., Midha, S., Laubach, J. P., & Richardson, P. G. G. (2024) · Cancers · doi:10.3390/cancers16061166 · Cited by 22
Self-citation
Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma
Gonsalves, W. I., Godby, K. N., Kumar, S. K., & Costa, L. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24129 · Cited by 20
Trial Watch: Proteasomal inhibitors for anticancer therapy
Obrist, F., Manic, G., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.974463 · Cited by 22
The pharmacologic management of multiple myeloma in older adults
Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 20
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0196-6 · Cited by 20
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
Li, Y., Liu, L., Wang, X., Zhang, C., Reyes, J. F., Hoffmann, M., Palmisano, M., & Zhou, S. Y. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1145 · Cited by 21
Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
Jiang, T., Su, H., Li, Y., Wu, Y., Ming, Y., Li, C., Fu, R., Feng, L., Li, Z., Li, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989032 · Cited by 21
Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis
Malard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 19
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 18
Self-citation
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex)
Sanchez, E., Li, M., Wang, C. S., Tang, G. Y., Gillespie, A., Chen, H., & Berenson, J. R. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.03.002 · Cited by 19
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
Kalff, A., Khong, T. T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R. Z., Wang, M., Couto, S. S., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571201 · Cited by 19
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
Soekojo, C. Y., Kım, K., Huang, S., Chim, C. S., Takezako, N., Asaoku, H., Kimura, H., Kosugi, H., Sakamoto, J., Gopalakrishnan, S. K., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0245-1 · Cited by 18
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
Fotiou, D., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221090089 · Cited by 18
Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
Mitsiades, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5748 · Cited by 18
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
Ichinohe, T., Kuroda, Y., Okamoto, S., Matsue, K., Iida, S., Sunami, K., Komeno, T., Suzuki, K., Ando, K., Taniwaki, M., et al. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0040-7 · Cited by 18
Self-citation
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 18
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Li, Y., Wang, X., O'Mara, E. M., Dimopoulos, M. A., Sonneveld, P., Weisel, K. C., Matous, J., Siegel, D. S. D., Shah, J. J., Kueenburg, E., et al. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s144606 · Cited by 17
Self-citation
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
Gueneau, P., Chrétien, M., Cransac, A., Aho, S., Lafon, I., Favennec, C., Guy, J., Caillot, D., & Boulin, M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13039 · Cited by 17
A validated UPLC–MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma
Iqbal, M., Ezzeldin, E., Al-Rashood, K. A. M., & Shakeel, F. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.12.036 · Cited by 17
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Seefat, M. R., Cucchi, D. G. J., Dirven, S., Groen, K., Zweegman, S., & Blommestein, H. M. (2021) · Cancers · doi:10.3390/cancers13225606 · Cited by 18
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
Hartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 17
Self-citation
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
Dimopoulos, M. A., Sonneveld, P., Siegel, D. S. D., Palumbo, A. P., & Miguel, J. F. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv325 · Cited by 16
Self-citation
Updates on thrombotic events associated with multiple myeloma
Fotiou, D., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Migkou, M., Dimopoulos, M. A., & Terpos, E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1604214 · Cited by 16
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Cancers · doi:10.3390/cancers14246216 · Cited by 17
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
Mark, T. M., Forsberg, P. A., Rossi, A., Pearse, R. N., Pekle, K. A., Perry, A., Boyer, A. S., Tegnestam, L., Jayabalan, D. S., Coleman, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028027 · Cited by 16
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
Ailawadhi, S., Mikhael, J. R., LaPlant, B. R., Laumann, K. M., Kumar, S. K., Roy, V., Dingli, D., Bergsagel, P. L., Buadi, F. K., Rajkumar, S. V., et al. (2017) · Leukemia · doi:10.1038/leu.2017.258 · Cited by 15
Self-citation
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
Minařík, J., Pour, L., Maisnar, V., Špıčka, I., Jungová, A., Jelı́nek, T., Brožová, L., Krhovská, P., Ščudla, V., & Hájek, R. (2018) · Biomedical Papers · doi:10.5507/bp.2018.064 · Cited by 15
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 15
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials
Zou, Y., Ma, X., Yu, H., Hu, C., Fan, L., & Ran, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10768 · Cited by 15
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
Matsue, K., Iwasaki, H., Chou, T., Tobinai, K., Sunami, K., Ogawa, Y., Kurihara, M., Midorikawa, S., Zaki, M. H., Doerr, T., et al. (2015) · Cancer Science · doi:10.1111/cas.12772 · Cited by 15
Self-citation
Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents
Liew, W. K. M., Pacak, C. A., Visyak, N., Darras, B. T., Bousvaros, A., & Kang, P. B. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.07.040 · Cited by 15
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials
Mushtaq, A., Iftikhar, A., Hassan, H., Lakhani, M., Sagar, F., Kamal, A., Zahid, U., Ali, Z., Razzaq, F., Zar, M. A., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.003 · Cited by 15
Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone
Thai, H., Gaudel‐Dedieu, N., Cerou, M., Ayral, G., Fau, J., Sébastien, B., de Velde, H. J. V., Sémiond, D., & Veyrat‐Follet, C. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15123 · Cited by 14
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
Goldman‐Mazur, S., Visram, A., Rajkumar, S. V., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00757-8 · Cited by 14
Self-citation
Risk assessment of venous thromboembolism in hematological cancer patients: a review
Chan, T. S. Y., Hwang, Y., & Tse, E. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1751608 · Cited by 14
Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma
Le, G. N., Bones, J., Coyne, M., Bazou, D., Dowling, P., O’Gorman, P., & Larkin, A. (2019) · Molecular Omics · doi:10.1039/c8mo00193f · Cited by 16
Pomalidomide in multiple myeloma
Uccello, G., Petrungaro, A., Mazzone, C., Recchia, A. G., Greco, R., Mendicino, F., Lucia, E., Vigna, E., Morabito, F., & Gentile, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1274973 · Cited by 14
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden Hospital experience
Sriskandarajah, P., Pawlyn, C., Mohammed, K., Dearden, C. E., Davies, F. E., Morgan, G. J., Boyd, K. D., & Kaiser, M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1198957 · Cited by 13
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Cope, S. F., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M., Weisel, K. C., & Jansen, J. P. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.003 · Cited by 13
To Market, To Market—2013
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 13
Practical Considerations in Managing Relapsed Multiple Myeloma
Agarwal, A., Chow, E., Bhutani, M., Voorhees, P. M., Friend, R. N., & Usmani, S. Z. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.010 · Cited by 15
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
Cohen, A., Spektor, T. M., Stampleman, L. V., Bessudo, A., Rosen, P. J., Klein, L. M., Woliver, T. B. S., Flam, M. S., Eshaghian, S., Nassir, Y., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14992 · Cited by 13
The use of Novel Agents in Multiple Myeloma Patients with Hepatic Impairment
Stansfield, L., Gonsalves, W. I., & Buadi, F. K. (2015) · Future Oncology · doi:10.2217/fon.14.270 · Cited by 13
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Handa, H., Ishida, T., Ozaki, S., Mori, A., Kato, K., & Iida, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283931 · Cited by 12
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study
Kikukawa, Y., Yuki, H., Hirata, S., Ide, K., Nakata, H., Miyakawa, T., Matsuno, N., Nosaka, K., Yonemura, Y., Kawaguchi, T., et al. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1705-9 · Cited by 12
Daratumumab in multiple myeloma
Rajkumar, S. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01226-x · Cited by 12
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
Markovic, U., Romano, A., Fabro, V. D., Bellofiore, C., Bulla, A., Parisi, M. S., Leotta, S., Gentile, M., Cangialosi, C., Vincelli, I. D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.624405 · Cited by 12

Authors: Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., Song, K., Belch, A., Raje, N., Shustik, C., Lentzsch, S., Lacy, M., Mikhael, J., Matous, J., Vesole, D., Chen, M., Zaki, M. H., Jacques, C., Yu, Z., & Anderson, K. C.
Affiliations: Dana-Farber Cancer Institute (US)
Hackensack University Medical Center (US)
Washington University in St. Louis (US)
The Ohio State University (US)
Moffitt Cancer Center (US)
Mount Sinai Medical Center, New York, NY;
Princess Margaret Cancer Centre (CA)
Emory University (US)
University of Chicago Medical Center (US)
University of Calgary (CA)
Vancouver General Hospital (CA)
University of Alberta (CA)
Massachusetts General Hospital (US)
Royal Victoria Hospital (CA)
Columbia University (US)
Mayo Clinic (US)
Colorado Blood Cancer Institute (US)
Celgene (United States) (US)
ORCID: Richardson, Paul G.
Siegel, David S.
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej
Bahlis, Nizar
Song, Kevin
Belch, Andrew
Raje, Noopur
Lentzsch, Suzanne
Lacy, Martha
Mikhael, Joseph
Vesole, David
Chen, Min
Jacques, Christian
Anderson, Kenneth C.
Venue: Blood
Publisher: American Society of Hematology
Published: 2014-03-20
Volume: 123
Issue: 12
Pages: 1826-1832
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2013-11-538835
PMC: PMC3962162
OpenAlex: W2091773528
Cited by: 381
References: 43
Citations by year: 2026: 7 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 39 · 2021: 30 · 2020: 31 · 2019: 24 · 2018: 30 · 2017: 54 · 2016: 48 · 2015: 48 · 2014: 27
FWCI: 41.83
Type: journal article
Language: en
Update notices: erratum (2014-05-15)
Open access: green
www.ncbi.nlm.nih.gov
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Celgene
National Cancer Institute (P50CA100707, P01CA155258, P30CA016058)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: pomalidomide, low-dose dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, lenalidomide-refractory disease, bortezomib resistance, combination therapy, neutropenia, peripheral neuropathy, overall survival, overall response rate
MeSH terms: Bortezomib, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Dexamethasone, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neutropenia, Pyrazines, Thalidomide, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks